These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 3026624)

  • 1. Buspirone in Parkinson's disease.
    Hammerstad JP; Carter J; Nutt JG; Casten GC; Shrotriya RC; Alms DR; Temple D
    Clin Neuropharmacol; 1986; 9(6):556-60. PubMed ID: 3026624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buspirone, Parkinson's disease, and the locus ceruleus.
    Ludwig CL; Weinberger DR; Bruno G; Gillespie M; Bakker K; LeWitt PA; Chase TN
    Clin Neuropharmacol; 1986; 9(4):373-8. PubMed ID: 2873889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buspirone in the treatment of tardive dyskinesia.
    Ross CA
    Med Hypotheses; 1987 Mar; 22(3):321-8. PubMed ID: 2884555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Manipulating the dopaminergic system in Parkinson's disease.
    Lang AE
    Pharmacol Ther; 1987; 32(1):51-76. PubMed ID: 3035589
    [No Abstract]   [Full Text] [Related]  

  • 5. Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.
    Shin E; Garcia J; Winkler C; Björklund A; Carta M
    Neurobiol Dis; 2012 Sep; 47(3):393-406. PubMed ID: 22579773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Chase TN
    Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease.
    Factor SA; Wolski K; Togasaki DM; Huyck S; Cantillon M; Ho TW; Hauser RA; Pourcher E
    Mov Disord; 2013 Jun; 28(6):817-20. PubMed ID: 23589371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure of buspirone to manage benzodiazepine withdrawal.
    Schweizer E; Rickels K
    Am J Psychiatry; 1986 Dec; 143(12):1590-2. PubMed ID: 2878622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of buspirone and placebo in relieving benzodiazepine withdrawal symptoms.
    Lader M; Olajide D
    J Clin Psychopharmacol; 1987 Feb; 7(1):11-5. PubMed ID: 2880872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buspirone: review of its pharmacology and current perspectives on its mechanism of action.
    Eison AS; Temple DL
    Am J Med; 1986 Mar; 80(3B):1-9. PubMed ID: 2870639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buspirone, a novel nonbenzodiazepine anxiolytic.
    Kastenholz KV; Crismon ML
    Clin Pharm; 1984; 3(6):600-7. PubMed ID: 6150781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.
    Addy C; Assaid C; Hreniuk D; Stroh M; Xu Y; Herring WJ; Ellenbogen A; Jinnah HA; Kirby L; Leibowitz MT; Stewart RM; Tarsy D; Tetrud J; Stoch SA; Gottesdiener K; Wagner J
    J Clin Pharmacol; 2009 Jul; 49(7):856-64. PubMed ID: 19491335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine neurotransmission and treatments for Parkinson's disease in the molecular biology era.
    Ogawa N
    Eur Neurol; 1997; 38 Suppl 1():2-5. PubMed ID: 9276193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
    Shin E; Lisci C; Tronci E; Fidalgo C; Stancampiano R; Björklund A; Carta M
    Neurobiol Dis; 2014 Feb; 62():233-40. PubMed ID: 24135006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
    Lees AJ; Tolosa E; Olanow CW
    Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
    de la Fuente-Fernández R; Sossi V; Huang Z; Furtado S; Lu JQ; Calne DB; Ruth TJ; Stoessl AJ
    Brain; 2004 Dec; 127(Pt 12):2747-54. PubMed ID: 15329355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.